|
Title
|
|
|
|
Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies : an update of the pivotal clinical trial data
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the ecacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Pharmaceutics
| |
|
Publication
|
|
|
|
Basel
:
Mdpi
,
2020
| |
|
ISSN
|
|
|
|
1999-4923
| |
|
DOI
|
|
|
|
10.3390/PHARMACEUTICS12020194
| |
|
Volume/pages
|
|
|
|
12
:2
(2020)
, p. 1-15
| |
|
Article Reference
|
|
|
|
194
| |
|
ISI
|
|
|
|
000519268500088
| |
|
Pubmed ID
|
|
|
|
32102267
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|